Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
The former Microsoft CEO launched "Just the Facts" with USAFacts to provide clear, factual information on key issues, like health, the economy, and immigration.
Research Director at CFRA Research, Ken Leon, joins Cheddar to discuss Disney's earnings plus the shake up happening at Warner Brothers Discovery. Watch!
OpenTable CEO joins Cheddar to discuss this summer's top restaurant trends, how best to make a reservation and what perks you can now get on the app. Watch!
Nancy Clark, President of Verizon Value, on Total Wireless’s rebranding and its commitment to top speeds, network quality, and value for prepaid customers.
"Your Money Playbook" by Brandon Copeland offers practical advice on earning, managing, and building wealth, drawing from his NFL career and business education.
